J. Leeman

发表

Alternative splicing in the NF-kappaB signaling pathway.

T. Gilmore, Thomas D Gilmore, Joshua R Leeman, 2008, Gene.

Isosteric replacements of the carboxylic acid of drug candidate VX-787: Effect of charge on antiviral potency and kinase activity of azaindole-based influenza PB2 inhibitors.

P. Charifson, Tiansheng Wang, E. Perola, 2015, Bioorganic & medicinal chemistry letters.

Alternative splicing in the NF- κ B signaling pathway

T. Gilmore, J. Leeman, 2009 .

Novel Ranking System for Identifying Efficacious Anti-Influenza Virus PB2 Inhibitors

P. Charifson, Steven J M Jones, Alice Tsai, 2015, Antimicrobial Agents and Chemotherapy.

Fragment-Based Discovery of Dual JC Virus and BK Virus Helicase Inhibitors.

E. ter Haar, J. Coll, R. Rijnbrand, 2016, Journal of medicinal chemistry.

Discovery of Novel, Orally Bioavailable β-Amino Acid Azaindole Inhibitors of Influenza PB2.

P. Charifson, Alice Tsai, Tiansheng Wang, 2017, ACS medicinal chemistry letters.

Novel 2-Substituted 7-Azaindole and 7-Azaindazole Analogues as Potential Antiviral Agents for the Treatment of Influenza.

F. Maltais, P. Charifson, Alice Tsai, 2017, ACS medicinal chemistry letters.

Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL's in vitro transforming activity

R. Siebert, L. Harder, C. Pott, 2007, Oncogene.

Deletion analysis and alternative splicing define a transactivation inhibitory domain in human oncoprotein REL

T. Barth, T. Gilmore, M. Weniger, 2008, Oncogene.

Preclinical Activity of VX-787, a First-in-Class, Orally Bioavailable Inhibitor of the Influenza Virus Polymerase PB2 Subunit

M. Murcko, P. Charifson, A. Kwong, 2014, Antimicrobial Agents and Chemotherapy.

Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2.

M. Murcko, F. Maltais, P. Charifson, 2014, Journal of medicinal chemistry.

Novel 2-Substituted 7-Azaindole and 7-Azaindazole Analogues as Potential Antiviral Agents for the Treatment of Influenza.

F. Maltais, P. Charifson, Alice Tsai, 2017, ACS medicinal chemistry letters.

Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2.

M. Murcko, F. Maltais, P. Charifson, 2014, Journal of medicinal chemistry.